Emergent Biosolutions (EBS)
(Delayed Data from NYSE)
$6.11 USD
+0.05 (0.83%)
Updated Sep 24, 2024 04:00 PM ET
Pre-Market: $6.61 +0.50 (8.18%) 8:56 AM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
Emergent Biosolutions (EBS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$8.00 | $8.00 | $8.00 | 30.93% |
Price Target
Only one analyst offered a short-term price target of $8.00 for Emergent Biosolutions. This represents an increase of 30.93% from the last closing price of $6.11.
Analyst Price Targets (1 )
Broker Rating
Emergent Biosolutions currently has an average brokerage recommendation (ABR) of 3.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by two brokerage firms. The current ABR compares to an ABR of 3.00 a month ago based on two recommendations.
Of the two recommendations deriving the current ABR, one is Strong Buy, representing 50% of all recommendations. A month ago, Strong Buy represented 50%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/20/2024 | The Benchmark Company | Robert Wasserman | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 3.00 |
ABR (Last week) | 3.00 |
# of Recs in ABR | 2 |
Average Target Price | $8.00 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 82 of 253 |
Current Quarter EPS Est: | 0.32 |
EBS FAQs
Emergent Biosolutions Inc. (EBS) currently has an average brokerage recommendation (ABR) of 3.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 2 brokerage firms.
The average price target for Emergent Biosolutions Inc. (EBS) is $8.00. The current on short-term price targets is based on 1 reports.
The forecasts for Emergent Biosolutions Inc. (EBS) range from a low of $8 to a high of $8. The average price target represents a increase of $30.93 from the last closing price of $6.11.
The current UPSIDE for Emergent Biosolutions Inc. (EBS) is 30.93%
Only one analyst offered a short-term price target of $8.00 for Emergent Biosolutions. This represents an increase of 30.93% from the last closing price of $6.11.